Sign in
Taking people in SpainPhase 2

Tests chemotherapy before surgery for locally advanced colon cancer

Tests chemotherapy given before surgery in adults with locally advanced colon cancer.

Key facts

Who runs it
Clinica Universidad De Navarra
Where
Badajoz, Burgos, Galdakao, León, Lugo, Madrid, Murcia, Oviedo, Palma, Pamplona, Salamanca, Talavera De La Reina, Valencia, Valladolid, and Vigo, SpainSee the 18 sites
Registry title
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER.
Status
Recruiting
Phase
Phase 2
People taking part
238 people, planned
Started
30 Jan 2025
Expected to end
31 Jul 2029
Type of study
Interventional
Record updated
30 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with locally advanced colon cancer that can be removed by surgery and has not spread to other organs.

Age
Over 18 years
Sex
All sexes can join
Disease stage
Colon adenocarcinoma confirmed by tissue test. The tumor is T4, or T3 growing more than 5 mm through the bowel wall on CT. Lymph nodes may or may not be involved. No spread to other organs (M0). Surgery with the aim of removing all the cancer must be planned.
Biomarker or test result
People with microsatellite instability cannot join.

Main reasons for not taking part

  • Rectal cancer
  • Distant metastasis or cancer spread inside the abdominal lining
  • Another cancer in the last 5 years, except melanoma
  • Intestinal obstruction
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Histological confirmation of colon adenocarcinoma
  • Radiologically resectable disease
  • Who are going to undergo elective surgery with curative intent (R0)
  • Patients of both sexes aged over 18 years
  • Good general condition of the patient (Karnofsky>60% or ECOG<2)
  • Analysis at the time of inclusion with hemoglobin levels >10 g/dL; Leukocytes >3.0 109/L, Platelets > 100,000, Glomerular Filtration >50 ml/min and Total Bilirubin <25 micromol/l
  • Absence of contraindication for chemotherapy
  • Acceptance and signing of the Informed Consent
  • Radiological signs, evaluated by CT, of T4 or T3 tumor infiltration >5 mm of transmural invasion
  • With or without lymph node involvement by CT
  • Without metastatic involvement in other organs (M0)

Who cannot take part

  • Significant comorbidity, uncontrolled angina or history of acute myocardial infarction in the last 6 months
  • Personal history of another neoplasm in the last 5 years, except for melanoma
  • Uncontrolled infection
  • Rectal cancer (< 15 cm from the anal verge or below the peritoneal reflection)
  • Refusal to participate or give written consent
  • Inability, at the discretion of the researcher, to understand the purpose of the study or comply with its procedures
  • Pregnancy or breastfeeding
  • Peripheral neuropathy > grade 1
  • Presence of distant metastasis or peritoneal carcinomatosis
  • Intestinal obstruction
  • Existence of microsatellite instability

Where in Spain

  • Hospital Universitario de BadajozBadajoz, SpainTaking people
  • Hospital Universitario De BurgosBurgos, SpainTaking people
  • Hospital de Galdakao-UsansoloGaldakao, SpainTaking people
  • Hospital Universitario De LeonLeón, SpainTaking people
  • Hospital Universitario Lucus AugustiLugo, SpainTaking people
  • Clinica Universidad de NavarraMadrid, SpainTaking people
  • Hospital Central de la Defensa Gómez UllaMadrid, SpainTaking people
  • Hospital Universitario Infanta LeonorMadrid, SpainTaking people
  • Hospital Universitario La PazMadrid, SpainTaking people
  • University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
  • Hospital Universitario Central De AsturiasOviedo, SpainTaking people
  • Hospital Son LlatzerPalma, SpainTaking people
  • Clínica Universidad de navarraPamplona, SpainTaking people
  • Hospital Universitario De SalamancaSalamanca, SpainTaking people
  • Hospital Nuestra Senona Del PradoTalavera De La Reina, SpainTaking people
  • Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
  • Hospital Universitario Rio HortegaValladolid, SpainTaking people
  • Hospital Alvaro CunqueiroVigo, SpainTaking people

About the trial

What the trial wants to find out

To determine if the proposed treatment with neoadjuvant chemotherapy, surgery and complementary chemotherapy increases Disease-Free Survival (DFS) at 2 years postoperatively, compared to the standard treatment, surgery and complementary chemotherapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER.
Plain-language title
Tests chemotherapy before surgery for locally advanced colon cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 January 2025